Gene Therapies Without Randomized Clinical Trials: Marks Outlines Rare Disease Development Path
A single-arm trial using a biomarker and animal model could be enough for an accelerated approval, especially in a pediatric rare disease where randomization and placebo controls may not be feasible, the CBER director said.